Focus on Optimized Dosing of Ibrutinib Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Nov

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

FDA Approves Durvalumab With FLOT for Resectable Gastric-GEJ Adenocarcinoma

AI Simplifies Patients Comprehension of CT Reports But Are Errors Possible

External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer

No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer

ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer